The global fetal bovine serum market size reached USD 1,054.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,651.2 Million by 2033, exhibiting a growth rate (CAGR) of 4.85% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1,054.7 Million |
Market Forecast in 2033
|
USD 1,651.2 Million |
Market Growth Rate 2025-2033 | 4.85% |
Fetal bovine serum (FBS) is a major component of animal cell culture media, which is obtained from bovine fetuses of cows. It has several nutritional and macromolecular factors that are essential for cell growth. Besides this, it also comprises amino acids, sugars, lipids, hormones, and low gamma globulin content. As a result, it is widely utilized in a range of applications, such as providing essential nutrients and facilitating cell survival and proliferation in eukaryotic cell culture. It is also used in research, manufacturing, biotech drugs, and controlling human and veterinary vaccines.
FBS finds application in generating stem cells for treating patients suffering from acute and chronic lung damage due to coronavirus disease (COVID-19). In addition, as it contains growth factors and antibodies that can be utilized in laboratories to keep cells alive for dividing, growing, and evolving, it plays a pivotal role in various scientific research. This, along with significant growth in the research and development (R&D) activities on account of increasing funding by governing and private agencies to introduce novel biopharmaceuticals, is catalyzing the demand for FBS worldwide. Furthermore, the escalating demand for biopharma products on account of the growing prevalence of acute and chronic diseases is contributing to the growth of the market. Apart from this, the emerging trend of nuclear families and inflating income levels are positively influencing pet ownership and humanization, which is resulting in the increasing adoption of companion animals across the globe. This, along with the rising consumption of animal-derived products, is anticipated to fuel the need for FBS in veterinary diagnostics and vaccines to prevent infectious diseases around the world.
IMARC Group provides an analysis of the key trends in each sub-segment of the global fetal bovine serum market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Atlas Biologicals Inc., Biological Industries (Sartorius AG), Bio-Techne Corporation, BioWest, Bovogen Biologicals Pty Ltd., General Electric Company, HiMedia Laboratories, Merck KGaA, PAN-Biotech, Rocky Mountain Biologicals, TCS Biosciences Ltd and Thermo Fisher Scientific Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Atlas Biologicals Inc., Biological Industries (Sartorius AG), Bio-Techne Corporation, BioWest, Bovogen Biologicals Pty Ltd., General Electric Company, HiMedia Laboratories, Merck KGaA, PAN-Biotech, Rocky Mountain Biologicals, TCS Biosciences Ltd and Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global fetal bovine serum market was valued at USD 1,054.7 Million in 2024.
We expect the global fetal bovine serum market to exhibit a CAGR of 4.85% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of fetal bovine serum to generate stem cells for treating the coronavirus-infected patients suffering from chronic lung damage.
The rising consumption of animal-derived products, along with increasing demand for fetal bovine serum in veterinary diagnostics and vaccines to prevent infectious diseases, is primarily driving the global fetal bovine serum market.
Based on the product, the global fetal bovine serum market can be categorized into charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, and others. Currently, charcoal stripped accounts for the majority of the total market share.
Based on the application, the global fetal bovine serum market has been segregated into biopharmaceuticals, cell culture, human and animal vaccine production, and others. Among these, biopharmaceuticals currently hold the largest market share.
Based on the end user, the global fetal bovine serum market can be bifurcated into biotechnology and pharmaceutical companies, academic institutes, research laboratories, and others. Currently, biotechnology and pharmaceutical companies exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global fetal bovine serum market include Atlas Biologicals Inc., Biological Industries (Sartorius AG), Bio-Techne Corporation, BioWest, Bovogen Biologicals Pty Ltd., General Electric Company, HiMedia Laboratories, Merck KGaA, PAN-Biotech, Rocky Mountain Biologicals, TCS Biosciences Ltd, and Thermo Fisher Scientific Inc.